Al Razi Medical Co (SAU:9572) EBIT: ﷼1.89 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SAU:9572 Al Razi Medical Co SAU:9572
45 GF Score
Price ﷼30.28
GF Value ﷼64.45
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Al Razi Medical Co EBIT?

Al Razi Medical Co SAU:9572 -0.13% 45 EBIT is ﷼1.89 Mil as of Dec. 2025. GuruFocus rates SAU:9572 with a GF Score™ of 45/100 and a GF Value™ of ﷼64.45 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Al Razi Medical Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was ﷼1.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was ﷼1.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Al Razi Medical Co's annualized ROC % for the quarter that ended in Dec. 2025 was 6.63%. Al Razi Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Al Razi Medical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 3.28%.

Al Razi Medical Co  (SAU:9572) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Al Razi Medical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=2.734 * ( 1 - 10.09% )/( (37.222 + 36.941)/ 2 )
=2.4581394/37.0815
=6.63 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=49.809 - 12.287 - ( 0.3 - max(0, 16.481 - 25.744+0.3))
=37.222

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=53.332 - 16.078 - ( 0.313 - max(0, 19.977 - 29.338+0.313))
=36.941

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Al Razi Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2.582/( ( (23.796 + max(12.015, 0)) + (23.789 + max(12.321, 0)) )/ 2 )
=2.582/( ( 35.811 + 36.11 )/ 2 )
=2.582/35.9605
=7.18 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.515 + 20.317 + 0.00099999999999767) - (12.287 + 0 + 0.531)
=12.015

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.425 + 23.643 + 0.951) - (16.078 + 0 + 0.62)
=12.321

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Al Razi Medical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=1.893/57.637
=3.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Al Razi Medical Co EBIT Related Terms

Al Razi Medical Co EBIT Historical Data

* Premium members only.

The historical data trend for Al Razi Medical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Al Razi Medical Co EBIT Chart

Al Razi Medical Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
2.73 1.56 1.04 1.89

Al Razi Medical Co Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 0.57 0.23 0.81 0.60 1.29

Al Razi Medical Co EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Al Razi Medical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Al Razi Medical Co EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Al Razi Medical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Al Razi Medical Co's EV-to-EBIT falls into.


SAU:9572
45GF Score
Al Razi Medical Co SAU:9572
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Al Razi Medical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ﷼1.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ﷼1.89 Mil mean?
Al Razi Medical Co (SAU:9572) has a EBIT of ﷼1.89 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Al Razi Medical Co.
Is Al Razi Medical Co's EBIT too high?
Al Razi Medical Co's current EBIT is ﷼1.89 Mil. Overall, Al Razi Medical Co has a GF Score™ of 45/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Al Razi Medical Co's EBIT compare to competitors?
Al Razi Medical Co's EBIT of ﷼1.89 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Al Razi Medical Co. Al Razi Medical Co's current EBIT is ﷼1.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Al Razi Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Al Razi Medical Co (SAU:9572) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼64.45, compared to a current price of ﷼30.28 — trading 53% below its estimated fair value. The current EBIT is ﷼1.89 Mil. Al Razi Medical Co's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Al Razi Medical Co (SAU:9572), the current EBIT is ﷼1.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Al Razi Medical Co (SAU:9572) Overvalued in 2026?

Based on GuruFocus' analysis, Al Razi Medical Co stock appears to be undervalued. The current stock price of ﷼30.28 is trading 53% below its estimated GF Value™ of ﷼64.45. GuruFocus considers Al Razi Medical Co to be Significantly Undervalued.

Key valuation signals for SAU:9572:

  • EBIT: ﷼1.89 Mil
  • GF Value™: ﷼64.45 vs. price of ﷼30.28 (53% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the SAU:9572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Al Razi Medical Co Business Description

Address King Abdulaziz Road, Al-Khaleej District, Al-Bada'ea, Al-Qassim, Riyadh, SAU
Al Razi Medical Co operates in the medical field in the Kingdom of Saudi Arabia. The company provides all pharmaceutical and cosmetic products. It engages in buying and selling pharmaceuticals, medical supplies, herbal and cosmetic products, and all related products on a wholesale and retail basis.
45GF Score

Get the complete analysis for SAU:9572

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼30.28
Price
﷼64.45
GF Value